stdClass Object
(
    [id] => 14493
    [paper_index] => 202412-01-019296
    [title] => REVIEW ON SUNITINIB-AN OVERVIEW OF ITS POTENTIAL THERAPEUTIC USES FOR THE MANAGEMENT OF RENAL CELL CARCINOMA AND GIST
    [description] => 
    [author] => Mr. Ritesh Popat Ghodke, Ms. Aishwarya Kamble, Dr. Sabale V. U
    [googlescholar] => 
    [doi] => 
    [year] => 2024
    [month] => December
    [volume] => 10
    [issue] => 12
    [file] => fm/jpanel/upload/2024/December/202412-01-019296.pdf
    [abstract] => Sunitinib is as tyrosine kinase inhibitor which is used in the treatment of certain types of cancer. Such as renal cell carcinoma (kidney cancer) and gastrointestinal stomal tumors (GISTS). Its works by blocking the action of abnormal protein. It helps to stop or slow the spread of cancel cell. Sunitinib is act as an antitumour or anti angiogenic activity because sunitinib is a protein kinase inhibitor and which work by block the action of abnormal proteins due to block the action that helps to stop or slow the spread of cancer cells and also helps to shrink.
    [keywords] => Renal Cell Carcinoma, Gastrointestinal Stomal Tumors, Angiogenic
    [doj] => 2024-12-05
    [hit] => 
    [status] => 
    [award_status] => P
    [orderr] => 10
    [journal_id] => 1
    [googlesearch_link] => 
    [edit_on] => 
    [is_status] => 1
    [journalname] => EPRA International Journal of Multidisciplinary Research (IJMR)
    [short_code] => IJMR
    [eissn] =>  2455-3662 (Online)
    [pissn] => - --
    [home_page_wrapper] => images/products_image/11.IJMR.png
)
Error fetching PDF file.